Studies have shown that fecal AHR agonist activity and the concentrations of key indole ligands such as IAA are significantly reduced in patients with metabolic syndrome (MetS) and patients in remission of inflammatory bowel disease (IBD) (Lamas et al., 2016). Here, AHR is linked to metabolic syndrome.